BPI Labs
United States 88 employees Updated 9 July 2026
BPI Labs is a finished-dose manufacturer based in United States. It appears in 16 regulatory filings across 1 regulator, without an active US DMF or CEP on file. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 23 April 2025 as VAI.
2
registered plants
2 with an FDA FEI number
16
filings
across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
3 of 3 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 23 April 2025 VAI US FDA
- 21 February 2025 NAI US FDA
- 10 March 2022 VAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Evanston, United States | 3008875046 |
| Largo, United States | 3015156709 |
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | 16 | 1 |
Comparing suppliers?
Choose your molecules and target markets. BPI Labs comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- 8 active litigation matters are on record.
- The most recent inspection outcome was VAI, on 23 April 2025.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates